Taysha Gene Therapies Inc. (TSHA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies: Shortened Timeline Increases The Potential
Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous pipeline. I rate TSHA as a Buy, citing strong cash reserves, promising early TSHA-102 data, and an accelerated FDA pathway skipping Phase 3. TSHA-102's miRARE technology offers a safety edge over competitor NGN-401, with pivotal data expected in late 2026 and potential commercialization by 2027/2028.
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 70 | $385 | $412.65 | $27.65 | 7.18% |
| BG Bart Gancher Intech Investment Management LLC | 47,988 | $81,391.17 | $284,568.84 | $203,177.67 | 249.63% |
 John H. Burbank III Passport Capital LLC | 4M | $10.57M | $23.75M | $13.18M | 124.67% |
 Point72 Asset Management LP Point72 Asset Management LP | 461,856 | $1.08M | $2.75M | $1.67M | 154.66% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 519,120 | $2.94M | $3.09M | $154,962.74 | 5.28% |
Taysha Gene Therapies Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JA Jack Allen Baird | 640,281.32 | $4.35M | $3.96M | -$384,632.63 | -8.85% |
| KT Keith Tapper BMO Capital | 14,781.53 | $101,401.27 | $88,245.71 | -$13,155.56 | -12.97% |
Taysha Gene Therapies Inc. (TSHA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Taysha Gene Therapies Inc. ever had a stock split?
Taysha Gene Therapies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sean Nolan CEO | NASDAQ (NGS) Exchange | 877619106 CUSIP |
| US Country | 99 Employees | - Last Dividend | - Last Split | 24 Sep 2020 IPO Date |
Overview
Taysha Gene Therapies, Inc. is a pioneering entity in the field of genomics, specifically focusing on adeno-associated virus-based gene therapies aimed at curing monogenic diseases of the central nervous system. The company's mission involves the development and commercialization of groundbreaking treatments that address the root causes of these genetic disorders. Through its strategic partnership with The University of Texas Southwestern Medical Center, Taysha is at the forefront of gene therapy research, seeking to bring transformative treatments from the lab bench to the patient's bedside. Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies is dedicated to pushing the boundaries of medicine to provide new hope for individuals affected by genetic neurological diseases.
Products and Services
- TSHA-120: Specifically designed for the treatment of giant axonal neuropathy, TSHA-120 showcases Taysha's dedication to addressing rare neurological disorders through targeted gene therapy interventions.
- TSHA-102: Developed for patients suffering from Rett syndrome, TSHA-102 reflects Taysha’s innovative approach to treating complex neurological conditions by correcting the underlying genetic abnormalities.
- TSHA-121: Focuses on the treatment of CLN1 disease, reflecting Taysha's commitment to combating Batten disease variants through its gene therapy products.
- TSHA-118: Another significant intervention for CLN1 disease, TSHA-118 underscores the company’s efforts in providing multiple therapeutic options for treating this form of Batten disease.
- TSHA-105: Targeted specifically at SLC13A5 Deficiency, TSHA-105 is an example of Taysha's dedication to exploring treatments for less known genetic disorders that affect the central nervous system.
- TSHA-101: Aiming to treat GM2 gangliosidosis, TSHA-101 demonstrates the company's focus on addressing genetic conditions that lead to significant neurological impairment, offering hope to affected patients and their families.
